KR100504379B1 - Microencapsulation of water-soluble isoflavone, production method thereof and application - Google Patents
Microencapsulation of water-soluble isoflavone, production method thereof and application Download PDFInfo
- Publication number
- KR100504379B1 KR100504379B1 KR10-2002-0084326A KR20020084326A KR100504379B1 KR 100504379 B1 KR100504379 B1 KR 100504379B1 KR 20020084326 A KR20020084326 A KR 20020084326A KR 100504379 B1 KR100504379 B1 KR 100504379B1
- Authority
- KR
- South Korea
- Prior art keywords
- water
- soluble
- isoflavones
- isoflavone
- microcapsules
- Prior art date
Links
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 title claims abstract description 112
- 235000008696 isoflavones Nutrition 0.000 title claims abstract description 112
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 title claims abstract description 53
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 6
- 239000003094 microcapsule Substances 0.000 claims abstract description 71
- 150000002515 isoflavone derivatives Chemical class 0.000 claims abstract description 59
- 239000011248 coating agent Substances 0.000 claims abstract description 35
- 238000000576 coating method Methods 0.000 claims abstract description 35
- 239000000463 material Substances 0.000 claims abstract description 30
- 239000000243 solution Substances 0.000 claims abstract description 21
- 239000004094 surface-active agent Substances 0.000 claims abstract description 13
- 239000006185 dispersion Substances 0.000 claims abstract description 12
- 239000007864 aqueous solution Substances 0.000 claims abstract description 10
- 238000005507 spraying Methods 0.000 claims abstract description 9
- 239000002775 capsule Substances 0.000 claims abstract description 7
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 238000003756 stirring Methods 0.000 claims abstract description 6
- 235000013336 milk Nutrition 0.000 claims description 23
- 239000008267 milk Substances 0.000 claims description 23
- 210000004080 milk Anatomy 0.000 claims description 23
- 235000013376 functional food Nutrition 0.000 claims description 14
- 229920000223 polyglycerol Polymers 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000011162 core material Substances 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 235000013618 yogurt Nutrition 0.000 claims description 4
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 3
- 229940057917 medium chain triglycerides Drugs 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 238000003860 storage Methods 0.000 description 15
- 230000001953 sensory effect Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 244000068988 Glycine max Species 0.000 description 7
- 235000010469 Glycine max Nutrition 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 6
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 6
- 208000001132 Osteoporosis Diseases 0.000 description 5
- 229920001214 Polysorbate 60 Polymers 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 235000019658 bitter taste Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 4
- 235000006539 genistein Nutrition 0.000 description 4
- 229940045109 genistein Drugs 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- AGNTUZCMJBTHOG-UHFFFAOYSA-N 3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]propane-1,2-diol Chemical compound OCC(O)COCC(O)COCC(O)CO AGNTUZCMJBTHOG-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 2
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 2
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 description 2
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- WUADCCWRTIWANL-UHFFFAOYSA-N biochanin A Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O WUADCCWRTIWANL-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000007240 daidzein Nutrition 0.000 description 2
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 208000025609 Urogenital disease Diseases 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- -1 fatty acid ester Chemical class 0.000 description 1
- 235000021105 fermented cheese Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 description 1
- 235000020189 fortified milk Nutrition 0.000 description 1
- 235000020604 functional milk Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000010150 least significant difference test Methods 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2116—Flavonoids, isoflavones
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 수용성 이소플라본이 함유된 미세캡슐, 이의 제조방법 및 응용에 관한 것이다.The present invention relates to a microcapsule containing a water-soluble isoflavone, a preparation method and an application thereof.
본 발명은 수용성 이소플라본이 함유된 미세캡슐, 이의 제조방법 및 수용성 이소플라본 미세캡슐을 유효성분으로 포함하는 기능성식품의 제공을 목적으로 한다.An object of the present invention is to provide a functional capsule containing a water-soluble isoflavone-containing microcapsules, a preparation method thereof and a water-soluble isoflavone microcapsules as an active ingredient.
본 발명의 수용성 이소플라본이 함유된 미세캡슐의 제조방법은The method for producing microcapsules containing water-soluble isoflavones of the present invention
(1)수용성 이소플라본을 코팅물질 용액에 첨가하는 단계와,(1) adding water-soluble isoflavones to the coating material solution,
(2)코팅물질과 수용성 이소플라본이 혼합된 용액을 교반한 후 계면활성제를 함유한 수용액 형태의 분산액에 분무하는 단계와,(2) stirring the solution mixed with the coating material and the water-soluble isoflavone and spraying the dispersion in the form of an aqueous solution containing a surfactant;
(3)코팅물질과 수용성 이소플라본이 분무된 분산액을 원심분리하여 캡슐화된 부분과 캡슐화 되지 않는 부분으로 분리하는 단계와,(3) separating the dispersion sprayed with the coating material and the water-soluble isoflavone into an encapsulated portion and an unencapsulated portion by centrifuging;
(4)전기의 (3)단계에 의해 캡슐화 된 부분을 (2)단계의 유화제에 분무하고 원심분리하는 단계를 포함한다.(4) spraying and encapsulating the part encapsulated by step (3) of the former in the emulsifier of step (2).
Description
본 발명은 수용성 이소플라본이 함유된 미세캡슐, 이의 제조방법 및 응용에 관한 것이다.The present invention relates to a microcapsule containing a water-soluble isoflavone, a preparation method and an application thereof.
이소플라본(isoflavone)은 식물체에 들어있는 색소(anthocyanin)의 한 종류인 페놀계 화합물의 배당체로써 대두중 약 0.1-0.3mg/g 정도가 함유되어 있으며 최근 유방암, 전립선암 등에 대한 항암작용, 동맥경화예방, 골다공증예방, 혈중알코올 농도조절의 효과가 있는 것으로 밝혀져 가장 주목을 받고 있는 물질이다.Isoflavone is a glycoside of phenolic compound, which is a kind of pigment (anthocyanin) contained in plants, and contains about 0.1-0.3mg / g of soybean, and it has anticancer activity against breast cancer and prostate cancer and arteriosclerosis. It has been found to be effective in preventing, preventing osteoporosis, and controlling blood alcohol concentration.
천연물에 존재하는 이소플라본은 genistein, daidzein, formononetin, biochanin A, genistin, daidzin 등이 있으며, 정도에 따라서 차이는 있지만 모두 약한 에스트로겐 활성을 가지고 있다. 특히 대두와 칡에는 genistein과 daidzein의 배당체인 genistin과 daidzin이 풍부한 것으로 알려져 있다. 대두의 항암작용은 최근 많은 주목을 받고 있는데, 이것은 대두에 있는 이소플라본, 단백질분해효소 억제제, phytate, 식이성 섬유, 사포닌, 식물성 스테롤, 페놀성 물질등에 기인하는 것으로 여겨지고 있다. 이중 유방암 또는 전립선암 등에 대해서 항암성을 보이는 것은 이소플라본이며, 주로 genistein에 의한 것으로 알려져 있다. 또한 genistein은 protein kinase와 DNA topoisomerase II의 작용을 방해하고 에스트로겐 수용체에 약하게 결합한다고 보고되고 있다.Isoflavones present in natural products include genistein, daidzein, formononetin, biochanin A, genistin, daidzin, and all have weak estrogen activity depending on the degree. Soybeans and soybeans are known to be rich in genistin and daidzin, the glycosides of genistein and daidzein. The anticancer activity of soybeans has recently received a lot of attention, which is believed to be due to isoflavones, protease inhibitors, phytate, dietary fiber, saponins, vegetable sterols, and phenolic substances in soybeans. Among the cancers of breast cancer or prostate cancer, isoflavones are known to be mainly caused by genistein. It has also been reported that genistein interferes with the action of protein kinase and DNA topoisomerase II and weakly binds to estrogen receptors.
여성은 50세를 전후하여 급격한 생리적인 변화를 수반하는 폐경기를 겪게 된다. 이 결과로 나타나는 여성호르몬 결핍은 동맥경화증, 비뇨생식기 질환, 우울증, 골다공증 등의 발생 위험을 증가시킨다. 특히 폐경기 이후 여성의 약 30% 정도에서 적어도 한번 이상의 골다공증에 의한 골절을 경험한다고 보고된바 있다.Women go through menopause with a rapid physiological change around age 50. The resulting female hormone deficiency increases the risk of developing atherosclerosis, genitourinary diseases, depression, and osteoporosis. In particular, about 30% of women after menopause have been reported to experience at least one osteoporosis fracture.
폐경기 이후 대부분의 여성에게 나타나는 갱년기 질환, 특히 골다공증은 조기 진단 및 예방의 중요성이 큰 비중을 차지하며, 부작용이 없이 장기 복용할 수 있는 골다공증 예방 및 치료제의 개발이 필요하다.Menopausal disease, especially osteoporosis, which occurs in most women after menopause, is of great importance for early diagnosis and prevention, and it is necessary to develop long-term osteoporosis prevention and treatment without side effects.
우유는 단백질, 지질, 당질, 비타민, 미네랄 등 사람에게 꼭 필요한 영양소의 전부를 균형 있게 함유하고 있기 때문에 완전식품이라고도 불린다. 우유는 특히 유아기의 성장발육에 있어서 중요한 역할을 담당하고 있다. 또 성장기의 청소년과 성인에 있어서도 균형 있는 영양의 보급이라는 관점에서 뛰어난 식품으로 분류되며, 고령자의 칼슘 보급원으로 아주 유효하다. 우리나라 우유생산은 1960년부터 시작하여 1990년에는 175만톤을 넘었고, 국민 1인당 우유소비는 2000년에는 59.2kg으로 계속적인 증가추세에 있다. 그리고 전체우유의 75%는 시유로 소비되고, 발효유, 치즈, 아이스크림 등의 가공 유제품 소비율은 낙농선진국에 비해 낮은편이다. 최근에는 백색우유의 증가는 미약한 편이나 성분조정유나 기능성 강화유의 소비는 꾸준히 증가하는 추세를 보이고 있어 기능성우유 품질을 다양화하려는 기술개발 및 실용화가 절실히 요구되고 있는 실정이다.Milk is also called a complete food because it contains all of the nutrients essential to humans, including proteins, lipids, sugars, vitamins and minerals. Milk plays a particularly important role in the growth and development of infancy. In addition, it is classified as an excellent food in terms of balanced distribution of adolescents and adults in the growing season, and is very effective as a source of calcium for the elderly. Korea's milk production started in 1960 and exceeded 1.75 million tons in 1990, and the per capita milk consumption in Korea is continuously increasing to 59.2kg in 2000. In addition, 75% of the whole milk is consumed as market milk, and the consumption rate of processed dairy products such as fermented milk, cheese, and ice cream is lower than that of dairy countries. In recent years, the increase in white milk is weak, but the consumption of ingredient-modified and functional fortified milk is steadily increasing. Therefore, there is an urgent need for technology development and commercialization to diversify functional milk quality.
폐경기 여성들의 골다공증을 예방하고 치유하기 위하여 부작용이 없는 식물성 에스트로겐인 이소플라본을 칼슘이 풍부한 우유에 첨가하는 것이 효과적이지만, 추출된 수용성 이소플라본은 고유의 쓴맛, 콩비린내, 아린맛, 그리고 진노란 색깔 등으로 아직까지 우유에 첨가가 이루어지지 못하였다. In order to prevent and cure osteoporosis in postmenopausal women, it is effective to add isoflavones, which are phytoestrogens, without side effects, to calcium-rich milk. It has not been added to milk yet.
본 발명은 우수한 기능성을 함유하고 있지만 독특한 관능성이 문제가 되어 직접 섭취가 불편한 수용성 이소플라본을 미세캡슐화 하고 이를 우유, 음료, 요구르트와 같은 기능성 식품에 첨가하여 우수한 기능성의 이소플라본을 함유한 기능성식품을 제공할 수 있다.The present invention is a functional food containing excellent functional isoflavones by containing microcapsules of water-soluble isoflavones, which contain excellent functionality but have a problem of unique functionalities, which are inconvenient to be consumed directly, and adding them to functional foods such as milk, beverage, and yogurt. Can be provided.
즉, 본 발명은 수용성 이소플라본이 함유된 미세캡슐, 이의 제조방법 및 수용성 이소플라본 미세캡슐을 유효성분으로 포함하는 기능성식품의 제공을 목적으로 한다. That is, an object of the present invention is to provide a functional capsule containing a water-soluble isoflavone-containing microcapsules, a preparation method thereof and a water-soluble isoflavone microcapsules as an active ingredient.
본 발명은 수용성 이소플라본이 함유된 미세캡슐, 이의 제조방법 및 응용으로서 수용성 미세플라본이 함유된 미세캡슐을 함유한 기능성 식품을 포함한다.The present invention includes a functional capsule containing a microcapsule containing a water-soluble isoflavone, a microcapsules containing a water-soluble microflavone as a preparation method and application thereof.
본 발명의 수용성 이소플라본이 함유된 미세캡슐은 미세캡슐 중량을 기준으로 10∼40 중량%의 수용성 이소플라본을 중심물질로 하고, 중심물질을 피막하는 코팅물질 60∼90 중량%로 이루어진다. 본 발명의 미세캡슐에 있어서 중심물질인 수용성 이소플라본이 10 중량% 미만이면 이소플라본을 미세캡슐화하는 의미가 없으며, 이소플라본이 40 중량% 초과하면 코팅물질의 함량이 감소하여 이소플라본의 충분한 코팅이 이루어지지 않아 본 발명에서 수용성 이소플라본은 미세캡슐 중량에 대하여 10∼40 중량% 포함하는 것이 바람직하다.The microcapsules containing the water-soluble isoflavones of the present invention are composed of 10 to 40% by weight of water-soluble isoflavones based on the weight of the microcapsules, and 60 to 90% by weight of the coating material for coating the core material. In the microcapsules of the present invention, if the water-soluble isoflavone is less than 10% by weight, it is not meaningful to microencapsulate the isoflavone. If the isoflavone exceeds 40% by weight, the content of the coating material decreases, so that sufficient coating of isoflavone is achieved. Since it is not made in the present invention, the water-soluble isoflavone preferably contains 10 to 40% by weight based on the weight of the microcapsules.
본 발명에서 미세캡슐의 코팅물질은 유화제를 이용할 수 있으며 본 발명에서는 이러한 유화제의 일예로서 폴리글리세롤 모노스테아레이트(PGMS) 또는 미디움-체인 트리아실글리세롤(MCT)을 사용할 수 있다.In the present invention, the coating material of the microcapsules may use an emulsifier, and in the present invention, polyglycerol monostearate (PGMS) or medium-chain triacylglycerol (MCT) may be used as an example of such an emulsifier.
본 발명의 수용성 이소플라본이 함유된 미세캡슐의 크기는 중심물질과 코팅물질의 사용량에 따라 조절할 수 있으며, 보다 좋게는 지름이 2∼5㎛인 크기를 가지는 미세캡슐이 바람직하다. 본 발명에서 미세캡슐의 크기가 2㎛ 미만이면 캡슐내부에 함유되는 수용성 이소플라본의 양이 감소하는 문제가 있고, 미세캡슐의 크기가 5㎛ 초과하면 기능성 식품에 미세캡슐을 첨가시 기능성 식품의 관능성이 감소할 수 있어 본 발명에서 수용성 이소플라본이 함유된 미세캡슐은 지름이 2∼5㎛인 크기를 가지는 것이 바람직하다.The size of the microcapsules containing the water-soluble isoflavone of the present invention can be adjusted according to the amount of the core material and the coating material, and more preferably, the microcapsules having a size of 2 to 5 μm in diameter are preferable. In the present invention, if the size of the microcapsules is less than 2㎛, the amount of water-soluble isoflavones contained in the capsule is reduced, and if the size of the microcapsules exceeds 5㎛, the functionality of the functional food when the microcapsules are added to the functional food Since the microcapsules containing water-soluble isoflavones in the present invention can be reduced, it is preferable that the microcapsules have a size of 2 to 5 μm in diameter.
본 발명의 수용성 이소플라본이 함유된 미세캡슐의 제조방법은The method for producing microcapsules containing water-soluble isoflavones of the present invention
(1)수용성 이소플라본을 코팅물질 용액에 첨가하는 단계와,(1) adding water-soluble isoflavones to the coating material solution,
(2)코팅물질과 수용성 이소플라본이 혼합된 용액을 교반한 후 계면활성제를 함유한 수용액 형태의 분산액에 분무하는 단계와,(2) stirring the solution mixed with the coating material and the water-soluble isoflavone and spraying the dispersion in the form of an aqueous solution containing a surfactant;
(3)코팅물질과 수용성 이소플라본이 분무된 분산액을 원심분리하여 캡슐화 된 부분과 캡슐화 되지 않는 부분으로 분리하는 단계와,(3) separating the dispersion sprayed with the coating material and the water-soluble isoflavone into an encapsulated portion and an unencapsulated portion by centrifuging;
(4)전기의 (3)단계에 의해 캡슐화된 부분을 (2)단계의 분산액에 분무하고 원심분리하는 단계를 이용하여 수용성 이소플라본이 함유된 미세캡슐을 얻을 수 있다.(4) The microcapsules containing water-soluble isoflavones can be obtained by spraying the part encapsulated by step (3) above into the dispersion of step (2) and centrifuging.
본 발명에서 수용성 이소플라본 제조시 코팅물질 3∼20g에 대하여 수용성 이소플라본을 1∼2g 첨가한다. 이때 코팅물질이 상온에서 고체일 경우에는 먼저 증류수 30∼70ml에 대하여 코팅물질 3∼20g을 용해시킨 다음 수용성 이소플라본을 첨가한다. 본 발명에서 코팅물질로 사용하는 미디움-체인 트리글리세롤은 상온에서 액체상태로 존재하여 바로 이소플라본을 첨가할 수 있지만 폴리글리세롤 모노스테아레이트는 상온에서 고체이므로 이를 코팅물질로 사용하는 경우 위에서 언급한 것처럼 폴리글리세롤 모노스테아레이트를 먼저 증류수에 용해시킨 후 수용성 이소플라본을 첨가한다.In preparing the water-soluble isoflavone in the present invention, 1 to 2 g of water-soluble isoflavone is added to 3 to 20 g of the coating material. At this time, if the coating material is a solid at room temperature, first dissolve the coating material 3 to 20g in 30 ~ 70ml of distilled water and then add the water-soluble isoflavones. Medium-chain triglycerol used as a coating material in the present invention can be added immediately isoflavones in the liquid state at room temperature, but polyglycerol monostearate is a solid at room temperature, so when used as a coating material as mentioned above Polyglycerol monostearate is first dissolved in distilled water and then water-soluble isoflavones are added.
코팅물질과 수용성 이소플라본이 혼합된 용액은 분무하기에 적당하도록 소정의 교반조건, 바람직하게는 1200∼2000rpm의 속도로 5분 이내로 교반한다. 교반이 끝나면 코팅물질과 수용성 이소플라본이 혼합된 용액은 분무기를 이용하여 저온의 계면활성제를 함유한 수용액에 분무한다. 계면활성제는 식품등급의 계면활성제를 이용할 수 있으며, 본 발명에서는 이러한 계면활성제의 일예로서 tween-60을 사용하여 수용성 이소플라본을 코팅하고 있는 코팅물질을 잘 분산시켜 치밀한 구조를 가지는 수용성 이소플라본 미세캡슐을 제조할 수 있다. 또한 본 발명에서 사용하는 계면활성제를 포함하는 분산액은 계면활성제의 농도를 0.05∼1.0%로 조절하여 사용하며, 수용성 이소플라본 미세캡슐의 제조를 위해 분산액의 온도는 5℃ 이하, 보다 좋게는 0∼5℃로 유지하는 것이 바람직하다.The solution mixed with the coating material and the water-soluble isoflavone is stirred in a predetermined stirring condition, preferably at a speed of 1200 to 2000 rpm, within 5 minutes so as to be suitable for spraying. After stirring, the solution mixed with the coating material and the water-soluble isoflavone is sprayed into an aqueous solution containing a low temperature surfactant by using a nebulizer. As the surfactant, food grade surfactant may be used. In the present invention, as an example of the surfactant, tween-60 is used to disperse the coating material coating the water-soluble isoflavone, so that the water-soluble isoflavone microcapsules have a compact structure. Can be prepared. In addition, the dispersion containing the surfactant used in the present invention is used by adjusting the concentration of the surfactant to 0.05 to 1.0%, the temperature of the dispersion for the production of water-soluble isoflavone microcapsules 5 ℃ or less, more preferably 0 ~ It is preferable to keep it at 5 degreeC.
코팅물질과 수용성 이소플라본이 혼합된 용액을 계면활성제를 함유한 수용액 형태의 분산액에 분무하면 분산액 내에서 수용성 이소플라본이 코팅물질에 의해 코팅되어 미세캡슐화 된다. 그 이후 분산액을 원심분리하여 캡슐화 된 부분과 캡슐화 되지 않는 부분으로 분리하면 수용성 이소플라본이 함유된 미세캡슐을 얻을 수 있다. 그리고 미세캡슐화 된 부분을 위에서 언급한 계면활성제를 함유한 분산액에 분무하고, 재차 원심분리 함으로써 수용성 이소플라본이 함유된 미세캡슐을 얻을 수 있다.Spraying the mixed solution of the coating material and the water-soluble isoflavone to the dispersion in the form of an aqueous solution containing a surfactant, the water-soluble isoflavone is coated by the coating material in the dispersion to be microencapsulated. Thereafter, the dispersion is centrifuged to separate the encapsulated and non-encapsulated portions to obtain microcapsules containing water-soluble isoflavones. Then, the microencapsulated portion is sprayed onto the dispersion containing the above-mentioned surfactant and centrifuged again to obtain microcapsules containing water-soluble isoflavones.
본 발명은 상기에서 언급한 수용성 이소플라본이 함유된 미세캡슐을 유효성분으로 포함하는 기능성 식품을 포함한다.The present invention includes a functional food comprising the above-mentioned microcapsules containing water-soluble isoflavones as an active ingredient.
본 발명에서 수용성 이소플라본이 함유된 미세캡슐은 우유, 요구르트, 음료 중에서 선택된 어느 하나의 기능성 식품에 첨가할 수 있다. 이때 미세캡슐의 첨가량은 기능성식품의 종류에 따라 다소 차이가 있을 수 있으나 일반적으로 기능성식품 100 중량부에 대하여 0.01∼5 중량부 첨가한다. 만일 0.01 중량부 미만 첨가하면 수용성 이소플라본이 함유된 미세캡슐을 첨가하는 의미가 없으며, 5 중량부 초과하여 첨가하면 미세캡슐의 첨가에 따른 유의적인 효과의 상승이 없으므로 수용성 이소플라본이 함유된 미세캡슐은 기능성식품 100 중량부에 대하여 0.01∼5 중량부 첨가하는 것이 좋다.In the present invention, the microcapsules containing water-soluble isoflavones may be added to any one functional food selected from milk, yogurt, and beverages. In this case, the amount of the microcapsules may vary slightly depending on the type of functional food, but is generally added in an amount of 0.01 to 5 parts by weight based on 100 parts by weight of the functional food. If it is added less than 0.01 parts by weight, it does not mean adding the microcapsules containing water-soluble isoflavones, and when added by more than 5 parts by weight, there is no significant effect of the addition of microcapsules, so the microcapsules containing water-soluble isoflavones are not added. It is good to add 0.01-5 weight part with respect to 100 weight part of silver functional foods.
이하 본 발명을 다음의 실시예 및 시험예에 의하여 설명하고자 한다. 그러나 이들은 본 발명의 일예로서 이들에 의해 본 발명의 권리범위가 한정되는 것은 아니다.Hereinafter, the present invention will be described by the following examples and test examples. However, these are only examples of the present invention, and the scope of the present invention is not limited thereto.
<실시예 1> PGMS를 이용한 수용성 이소플라본의 미세캡슐Example 1 Microcapsules of Water-Soluble Isoflavones Using PGMS
폴리글리세롤 모노스테아레이트(polyglycerol monostearate, PGMS, 일신유화 제품) 5g, 10g, 15g, 20g을 각각 50ml의 증류수와 혼합하였다. 혼합 후 55℃에서 20분간 정치시키고 1200rpm의 속도로 1분간 교반하여 분무가 가능하도록 PGMS를 충분히 용해하였다.5 g, 10 g, 15 g, and 20 g of polyglycerol monostearate (polyglycerol monostearate, PGMS, Ilshin Emulsification) were respectively mixed with 50 ml of distilled water. After mixing, the mixture was allowed to stand at 55 ° C. for 20 minutes and stirred for 1 minute at a speed of 1200 rpm to sufficiently dissolve PGMS to enable spraying.
각각의 PGMS 용액에 30%의 수용성 이소플라본(입수처 : (주) 태평양)을 1g을 첨가한 다음 1200rpm으로 1분간 교반하였다.To each PGMS solution was added 1 g of 30% water-soluble isoflavone (available from Pacific), and then stirred at 1200 rpm for 1 minute.
교반 후 수용성 이소플라본이 첨가된 PGMS 용액을 분무기(W-300, Wagner Spray Tech. Co. Markdorf. Germany)로 계면활성제인 0.05%의 Tween-60(일신유화 제품)을 함유한 5℃의 수용액에 분무하여 분산시켰다.After stirring, the PGMS solution to which the water-soluble isoflavone was added was sprayed (W-300, Wagner Spray Tech. Co. Markdorf. Germany) into an aqueous solution at 5 ° C containing 0.05% of Tween-60 (Ishinshin Oil Products) as a surfactant. Sprayed to disperse.
전기의 수용성 이소플라본과 PGMS이 분무된 유화제를 24900×g에서 10분간 원심분리하여 캡슐화 되지 않은 상등액과 캡슐화 된 여액을 분리하였다. 캡슐화 된 여액을 0.05%의 Tween-60이 용해된 5℃의 수용액에 분무하고 이를 다시 24900×g에서 10분간 원심분리하여 수용성 이소플라본이 함유된 미세캡슐을 제조하였다.The water-soluble isoflavones and PGMS sprayed emulsifier were centrifuged at 24900 × g for 10 minutes to separate the unencapsulated supernatant and the encapsulated filtrate. The encapsulated filtrate was sprayed into an aqueous solution at 5 ° C. in which 0.05% of Tween-60 was dissolved and centrifuged at 24900 × g for 10 minutes to prepare microcapsules containing water-soluble isoflavones.
<실시예 2> MCT를 이용한 수용성 이소플라본의 미세캡슐Example 2 Microcapsules of Water-Soluble Isoflavones Using MCT
액상의 미디움-체인 트리글리세롤(Medium-chain triglycerol, MCT, 일신유화 제품) 5g, 10g, 15g, 20g에 30%의 수용성 이소플라본(입수처 : (주) 태평양) 1g을 각각 혼합하여 2000rpm의 속도로 1분간 교반하였다. 각각의 혼합액을 분무기(W-300)로 계면활성제인 0.05%의 Tween-60(일신유화 제품)을 함유한 5℃의 수용액에 분무하였다.2000rpm speed by mixing 1g of 30% water-soluble isoflavone (Pacific Co., Ltd.) in 5g, 10g, 15g, 20g of liquid medium-chain triglycerol (MCT) Stirred for 1 minute. Each mixed solution was sprayed with an atomizer (W-300) into an aqueous solution at 5 ° C. containing 0.05% of Tween-60 (produced by Ilshin Emulsifier) as a surfactant.
그런 다음 4520×g에서 10분간 원심분리하여 캡슐화 된 상층부와 캡슐화 되지 않은 여액으로 분리하였다. 캡슐화된 상층부를 0.05%의 Tween-60(일신유화 제품)이 용해된 5℃의 수용액에 분무하고 4520×g에서 10분간 원심분리하여 수용성 이소플라본이 함유된 미세캡슐을 제조하였다.It was then centrifuged at 4520 × g for 10 minutes to separate the encapsulated upper layer and the unencapsulated filtrate. The encapsulated upper layer was sprayed into an aqueous solution at 5 ° C. in which 0.05% of Tween-60 (Ilshin Emulsification) was dissolved and centrifuged at 4520 × g for 10 minutes to prepare microcapsules containing water-soluble isoflavones.
<시험예 1> 미세캡슐의 수율Test Example 1 Yield of Microcapsules
실시예 1 및 실시예 2에서 얻은 수용성 이소플라본이 함유된 미세캡슐의 수율을 측정하여 이를 아래의 표 1, 2에 나타내었다. 이소플라본이 함유된 미세캡슐의 수율은 수용성 이소플라본을 분무한 수용액에서 미세캡슐 외부용액에 존재하는 수용성 이소플라본의 양을 측정하여 미세캡슐 내부에 존재하는 수용성 이소플라본의 양을 계산하는 방법을 사용하였다.The yields of the microcapsules containing water-soluble isoflavones obtained in Examples 1 and 2 were measured and shown in Tables 1 and 2 below. Yield of isoflavone-containing microcapsules is calculated by measuring the amount of water-soluble isoflavones present in the external solution of microcapsules in an aqueous solution sprayed with water-soluble isoflavones. It was.
먼저, 원심분리 후 미세캡슐을 제외한 용액을 적당량 취하여 HPLC의 시료로 사용하였다. HPLC의 결과, 시료의 각 피크의 면적을 표준물질과 비교하여 수용성 이소플라본의 캡슐화 수율을 측정하였다.First, an appropriate amount of the solution except the microcapsules after centrifugation was taken and used as a sample of HPLC. As a result of HPLC, the area of each peak of the sample was compared with the standard to measure the encapsulation yield of the water-soluble isoflavones.
수용성 이소플라본의 HPLC에 의한 분석은 Yi등(36)의 방법(Kwak H S, Ihm M R. β-D-galactosidase microencapsulated with fatty acid ester and milk containing the same. US patent No : 6,491,955)을 수정 보완한 gradient solvent system으로 분석하였다. 분석시 사용된 칼럼(column)은 Waters사(U.S.A.)의 μ-Bondapak C18 column이고, 디텍터(detecter)는 254nm UV detector(Shimazu, Japan)를 사용하였으며, injection volume은 20㎕로 하였다. 이동상(mobile phase) A, B는 각각 20% 메탄올과 60% 메탄올을 사용하였다. solvent gradient는 시료주입후 이동상 A를 100으로 시작하여 50분까지 이동상 B가 100으로 직선적으로 상승 시켰으며, 그 후 60분까지 이동상 A를 100%로 하였으며, 그 후 65분까지 이동상 A를 100%로 유지하여 디텍터와 칼럼을 안정화 시켰다. HPLC analysis of water-soluble isoflavones was a modified and supplemented method of Yi et al. (36) (Kwak HS, Ihm M R. β-D-galactosidase microencapsulated with fatty acid ester and milk containing the same.US patent No: 6,491,955). Analysis was performed with a gradient solvent system. The column used for the analysis was a μ-Bondapak C18 column of Waters (U.S.A.), a detector was used with a 254nm UV detector (Shimazu, Japan), and the injection volume was 20 μl. Mobile phases A and B used 20% methanol and 60% methanol, respectively. After the sample injection, the solvent gradient started from mobile phase A to 100, and then mobile phase B was linearly increased to 100 by 50 minutes, then mobile phase A was 100% by 60 minutes, and then mobile phase A was 100% by 65 minutes. Stabilizer and the column was stabilized by maintaining.
표 1. 실시예 1에서 제조한 수용성 이소플라본이 함유된 미세캡슐의 수율Table 1. Yield of microcapsules containing water-soluble isoflavones prepared in Example 1
표 2. 실시예 2에서 제조한 수용성 이소플라본이 함유된 미세캡슐의 수율Table 2. Yield of microcapsules containing water-soluble isoflavones prepared in Example 2
<시험예 2> 인공위액에서의 미세캡슐의 안정성Test Example 2 Stability of Microcapsules in Artificial Gastric Fluids
수용성 이소플라본 미세캡슐의 안정성은 인공위액의 pH와 배양(incubation) 시간에 따라 미세캡슐로부터 수용성 이소플라본의 방출량을 측정하는 방법을 이용하여 실시하여 그 결과를 도 1에 나타내었다.The stability of the water-soluble isoflavone microcapsules was carried out using a method of measuring the release amount of the water-soluble isoflavone from the microcapsules according to the pH of the gastric juice and the incubation time, and the results are shown in FIG. 1.
증류수 2㎖에 실시예 1에서 제조한 수용성 이소플라본 미세캡슐 20mg 및 4ml의 pepsin용액(pH 1.2, 1mg/ml)을 첨가한 후, 1N HCl로 수용성 이소플라본 미세캡슐이 용해된 용액의 pH를 2, 3, 4, 5으로 조절하였다. 위의 용액을 각각 37℃ 항온수조에서 각 시간별로(0, 20, 40, 60분) 배양(미세피복 된 철분을 첨가한 요구르트의 저장 중 품질변화. 김윤지, 윤칠석. 1999. J. Korean Soc. Food Sci. Nutr. 28(3) : 542-546.)하면서 용액에 방출된 수용성 이소플라본을 시험예 1에서 언급한 HPLC에 의한 방법으로 정량하였다.After adding 20 mg of water-soluble isoflavone microcapsules prepared in Example 1 and 4 ml of pepsin solution (pH 1.2, 1 mg / ml) to 2 ml of distilled water, the pH of the solution in which the water-soluble isoflavone microcapsules was dissolved in 1N HCl was 2 , 3, 4, and 5 were adjusted. The above solution was incubated at 37 ° C in a constant temperature water bath each time (0, 20, 40, 60 minutes) (quality change during storage of yogurt containing micro-coated iron. Yun-ji Kim, Chil-seok Yoon. 1999. J. Korean Soc. Water soluble isoflavones released in the solution under Food Sci.Nutr. 28 (3): 542-546.) Were quantified by the HPLC method mentioned in Test Example 1.
<시험예 3> 인공소장액에서의 미세캡슐의 안정성Test Example 3 Stability of Microcapsules in Artificial Small Intestine
수용성 이소플라본이 함유된 미세캡슐의 인공소장액에서 안정성은 하기와 같이 측정하여 이를 도 2에 나타내었다.Stability in the artificial intestine of the microcapsules containing water-soluble isoflavones is measured as shown in Figure 2 as shown.
시험예 2에서 인공위액으로 각각 다른 pH와 시간별로 배양된 용액에 0.02M 콜릭산(cholic acid), 0.02M 디옥시콜릭산(deoxycholic acid, bile salt), 5mg 리파제(lipase) 및 판크레아틴(pancreatin) 용액(1mg/ml phosphate buffer, pH 7.4)을 첨가하였다. 1N 염산과 1N 수산화나트륨으로 이 용액의 pH를 6, 7, 8으로 조정한 후 37℃에서 각 시간(0, 20, 40, 60분)별로 배양하면서 수용성 이소플라본을 HPLC에 의해 정량하였다. In Test Example 2, 0.02M cholic acid, 0.02M deoxycholic acid (bile salt), 5mg lipase, and pancreatin (pancreatin) were added to the solution incubated at different pH and time with artificial gastric juice. ) Solution (1 mg / ml phosphate buffer, pH 7.4) was added. The pH of this solution was adjusted to 6, 7, 8 with 1N hydrochloric acid and 1N sodium hydroxide, followed by incubation at 37 ° C. for each hour (0, 20, 40, 60 minutes) to quantify the water-soluble isoflavones by HPLC.
<시험예 4><Test Example 4>
상기 실시예 1에서 제조한 수용성 이소플라본을 함유한 미세캡슐 4℃, 20℃ 및 30℃의 온도 조건으로 1일, 3일, 5일, 8일, 12일 동안 저장하면서 저장기간에 따른 수용성 이소플라본의 유리량을 파악하여 관능적으로 미치는 영향을 조사하였으며 그 결과를 도 3에 나타내었다.Microcapsules containing water-soluble isoflavones prepared in Example 1 Water-soluble isoflavone according to the storage period while storing for 1 day, 3 days, 5 days, 8 days, 12 days at temperature conditions of 4 ℃, 20 ℃ and 30 ℃ The amount of flavone was grasped and the sensory effect was investigated. The results are shown in FIG. 3.
도 3에서처럼 수용성 이소플라본 미세캡슐의 저장을 위한 최적온도는 4℃ 임을 알 수 있다.As shown in Figure 3 it can be seen that the optimum temperature for the storage of the water-soluble isoflavone microcapsules is 4 ℃.
<시험예 5><Test Example 5>
우유 100 중량부에 아무것도 첨가하지 않은 것을 대조구로 하고, 상기 실시예 1에서 제조한 수용성 이소플라본 미세캡슐 1 중량부를 우유 100 중량부에 첨가한 것을 실험군 1, 이소플라본 1g을 우유 100 중량부에 첨가한 것을 실험군 2로 하였다. 대조구, 실험군 1 및 실험군 2를 4℃의 온도 조건으로 1일, 3일, 5일, 8일, 12일 동안 저장하면서 나타나는 이미와 이취의 정도, 기호도 등의 관능적 특성변화를 측정하고 이를 하기의 표 3에 나타내었다.Nothing was added to 100 parts by weight of milk as a control, and 1 part by weight of water-soluble isoflavone microcapsules prepared in Example 1 was added to 100 parts by weight of milk. Experiment 1 and 1 g of isoflavones were added to 100 parts by weight of milk. What was done was experimental group 2. The control group, experimental group 1 and experimental group 2 were measured at 4 ° C. for 1 day, 3 days, 5 days, 8 days, and 12 days, and sensory characteristics such as degree of odor and taste were measured. Table 3 shows.
관능검사 요원은 우유의 맛을 구별할 수 있는 사람 20인(남녀 각각 10명)을 선발한 후 10일 동안 훈련을 시켜 관능검사를 실시하였다. 관능적 특성의 평가는 9점 평점법으로 하였으며 관능검사로 얻은 결과의 분석은 SAS를 이용하여 분산분석과 최소유의차 검정으로 통계처리 하였다.Sensory test personnel were selected 20 people (10 men and women each) who can distinguish the taste of milk, and trained for 10 days to conduct a sensory test. Sensory characteristics were evaluated by 9-point scoring method, and the results of sensory evaluation were analyzed statistically by analysis of variance and least significant difference test using SAS.
표 3. 수용성 이소플라본 미세캡슐을 포함하는 우유의 관능검사 결과Table 3. Sensory test results of milk containing water-soluble isoflavone microcapsules
* 1: 아무 변화 없음, 3: 약간 있음, 5: 중간, 7: 강하다. 9:매우 강하다.* 1: No change, 3: Slightly present, 5: Medium, 7: Strong. 9: Very strong.
상기 표 3에서처럼 쓴맛(bitterness)의 경우 저장기간 증가에 따른 변화는 모든 실험군에서 거의 없었다. 실험군간 차이도 저장 12일 간 크지 않았다. 이것은 수용성 이소플라본이 코팅물질의 시간경과에 따른 파괴에도 다른 이취를 생성하지는 않음을 의미하며, 우유 고유의 향미에 쓴맛에 대한 관능적 변화가 없음을 의미한다.In the case of bitterness (bitterness) as shown in Table 3 there was little change with increasing storage period in all experimental groups. Differences between experimental groups were also not significant for 12 days of storage. This means that the water-soluble isoflavones do not produce other off-flavors even after breakdown of the coating over time, and there is no sensory change in the bitter taste of the milk's inherent flavor.
색깔(color)의 경우 이소플라본은 고유의 갈색을 띠고 있는 특성을 지니고 있어, 저장기간 증가에 따른 색깔변화는 중요한 의미를 갖는다. 이소플라본을 첨가한 실험군 2는 저장기간 증가에 따라 점차적으로 갈색을 띠는 것으로 평가되었다. 특히 저장기간 6일 이후에는 대조구에 비해 현저하게 갈색으로 변화되어 우유의 관능적 성질에 큰 유의차를 보였다. 수용성 이소플라본 미세캡슐을 첨가한 실험군 1은 육안으로 판단하기 어려울 정도의 미묘한 유의차를 나타내었으며 9일 이후에는 관능적인 유의차를 약간 보였다. 이것은 저장기간이 길어짐에 따라 코팅물질의 파괴와 함께 이소플라본이 우유 내부로 유출되기 때문이다.In the case of color, isoflavones have inherent brown color, so the change of color with increasing storage period is important. Experimental group 2 with isoflavones was evaluated to have a brown color gradually with increasing storage period. In particular, after 6 days of storage, the color changed to brown compared to the control, which showed a significant difference in the sensory properties of milk. Experimental group 1 with water-soluble isoflavone microcapsules showed a subtle difference that was difficult to judge with the naked eye and showed a slight sensory difference after 9 days. This is because isoflavones leak into the milk with the destruction of the coating material as the storage period becomes longer.
콩비린내(beany flavor)의 경우 실험군 2는 저장 1일부터 대조구와 비교하여 현저하게 유의차를 보였으며, 저장기간이 증가함에 따라 콩비린내도 증가하였다. 한편, 실험군 1은 대조구와 비교하였을 때 약간의 유의차를 보였으나, 저장기간 증가함에 따라 콩비린내 역시 서서히 증가하였다. 저장 후 3일까지는 거의 변화가 없었으며, 6일이 경과하면서 서서히 증가하는 추세를 보였으나 제품의 상태를 크게 변화시키지는 못하였다.In case of beany flavor, experimental group 2 showed significant difference compared to the control group from day 1, and soybean odor increased as storage period increased. On the other hand, the experimental group 1 showed a slight difference compared to the control, but as the storage period increased, soybean odor also increased slowly. There was little change until 3 days after storage, and it showed a tendency to increase gradually after 6 days, but it did not change the state of the product significantly.
관능검사의 결과를 종합하면, 캡슐화된 이소플라본은 저장기간에 따라 쓴맛은 거의 변화가 없으며, 이소플라본 특유의 콩비린내와 색깔의 변화가 캡슐화함으로써 관능적으로 거의 대조구와 유의차를 보이지 않아 우유에 수용성 이소플라본 미세캡슐의 첨가가 유효함을 알 수 있다. The results of sensory evaluation showed that the encapsulated isoflavones had little change in the bitter taste according to the storage period. It can be seen that the addition of isoflavone microcapsules is effective.
상기 실시예 및 시험예의 결과로부터 본 발명의 수용성 이소플라본 미세캡슐은 기능성식품 특히 우유에 첨가시 우유의 관능특성을 저하시키지 않으면서 이소플라본의 섭취를 용이하다. 따라서 종래 유용한 이소플라본을 쉽게 섭취할 수 있는 장점이 있다.The water-soluble isoflavone microcapsules of the present invention from the results of the above examples and test examples facilitate the ingestion of isoflavones without reducing the sensory properties of milk when added to functional foods, especially milk. Therefore, there is an advantage that can easily consume conventionally useful isoflavones.
도 1은 인공위액에서 pH와 배양시간에 따라 수용성 이소플라본 미세캡슐로부터 수용성 이소플라본의 방출량을 나타낸 그래프이다.1 is a graph showing the release amount of water-soluble isoflavones from water-soluble isoflavone microcapsules according to pH and incubation time in artificial gastric juice.
도 2는 인공소장액에서 pH와 배양시간에 따라 수용성 이소플라본 미세캡슐로부터 수용성 이소플라본의 방출량을 나타낸 그래프이다.Figure 2 is a graph showing the release amount of water-soluble isoflavones from water-soluble isoflavone microcapsules according to pH and incubation time in artificial intestine.
도 3은 온도 및 저장기간에 따라 수용성 이소플라본 미세캡슐로부터 수용성 이소플라본의 유리량을 나타낸 그래프이다.3 is a graph showing the free amount of water-soluble isoflavones from water-soluble isoflavone microcapsules according to temperature and storage period.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2002-0084326A KR100504379B1 (en) | 2002-12-26 | 2002-12-26 | Microencapsulation of water-soluble isoflavone, production method thereof and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2002-0084326A KR100504379B1 (en) | 2002-12-26 | 2002-12-26 | Microencapsulation of water-soluble isoflavone, production method thereof and application |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040057565A KR20040057565A (en) | 2004-07-02 |
KR100504379B1 true KR100504379B1 (en) | 2005-07-28 |
Family
ID=37350132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2002-0084326A KR100504379B1 (en) | 2002-12-26 | 2002-12-26 | Microencapsulation of water-soluble isoflavone, production method thereof and application |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100504379B1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110999967A (en) * | 2019-12-02 | 2020-04-14 | 华中农业大学 | Yoghourt containing essential oil microcapsules |
KR102128253B1 (en) * | 2020-01-31 | 2020-06-30 | 주식회사 에스엘 | Seomoktae beverage containing isoflavones related to bone health and female hormones |
CN112155209A (en) * | 2020-09-11 | 2021-01-01 | 北京瑞草科技有限公司 | Ginkgo extract microcapsule with high flavone content and preparation method and application thereof |
-
2002
- 2002-12-26 KR KR10-2002-0084326A patent/KR100504379B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20040057565A (en) | 2004-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6787151B2 (en) | Composition for lowering blood cholesterol | |
Wollgast et al. | Polyphenols in chocolate: is there a contribution to human health? | |
Sosnowska et al. | Inhibitory effect of black chokeberry fruit polyphenols on pancreatic lipase–Searching for most active inhibitors | |
Vitaglione et al. | Human bioavailability of flavanols and phenolic acids from cocoa-nut creams enriched with free or microencapsulated cocoa polyphenols | |
Mrduljaš et al. | Polyphenols: Food sources and health benefits | |
US6001368A (en) | Method for inhibiting or reducing the risk of macular degeneration | |
CN100471850C (en) | Epigallocatechin dimers or trimers having lipase inhibitory activity and/or antioxidative activity | |
Wanasundara et al. | Endogenous antioxidants from oilseeds and edible oils | |
EP1767204B1 (en) | Lipase inhibitors | |
CN102427807B (en) | Anti-obesity agent comprising compound containing benzotropolone ring | |
AU2002325486A1 (en) | Composition for lowering blood cholesterol | |
EP1772148A1 (en) | Lipase inhibitors | |
AU2007245223B2 (en) | Fat absorption inhibitor | |
TW201043144A (en) | A method for producing a nutraceutical composition and the nutraceutical produced by the method | |
CN107048383A (en) | For strengthen EGCg to slow down skeletal muscle loss effect method | |
Epriliati et al. | Bioavailability of phytochemicals | |
Wyspiańska et al. | Effect of microencapsulation on concentration of isoflavones during simulated in vitro digestion of isotonic drink | |
JP2000325039A (en) | Anti-arteriosclerotic food | |
KR20040093116A (en) | Process for producing sdg and foods and drinks containing the same | |
KR101093009B1 (en) | Composition for preventing and relieving of menopausal symptoms comprising glyceollin | |
KR100504379B1 (en) | Microencapsulation of water-soluble isoflavone, production method thereof and application | |
US20020160060A1 (en) | Enriched spreads | |
MXPA04002145A (en) | Isoflavone concentrate and method for production thereof. | |
KR20040101694A (en) | A food containing -renolenic acid for a climacteric woman | |
JP2003153650A (en) | Edible oil and fat, and food product using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
LAPS | Lapse due to unpaid annual fee |